-Increase in β-CTX and osteocalcin, BMD reduction (canagliflozin); no effects on BTMs and BMD (other molecules); no effects on bone quality-CKD: reduced risk of dialysis, transplantation, AKI, and mortality. This evidence concerns the gene BGLAP and chronic kidney disease.